Octreoscan (Indium In-111 Pentetreotide)

Indium In-111 pentetreotide, the active ingredient in Octreoscan, is a somatostatin analog presented as a radiopharmaceutical for intravenous use. It is employed in diagnostic imaging to locate neuroendocrine tumours and assess somatostatin receptor expression in adult patients. GNH USA supplies Octreoscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Octreoscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Octreoscan is used in nuclear medicine to image neuro‑endocrine tumours that express somatostatin receptors.

- Gastroenteropancreatic neuroendocrine tumours: helps detect the extent of disease and guides therapeutic planning. - Carcinoid syndrome tumours: assists in localising tumour sites for surgical or medical management. - Metastatic neuroendocrine lesions: aids in staging and evaluating treatment response.

Side effects are generally mild and related to the radiopharmaceutical nature of the preparation.

Common Side Effects: - Nausea - Transient flushing of the face - Mild abdominal pain - Localised injection site discomfort - Low‑grade headache - Temporary fatigue

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Significant hypotension - Acute renal injury due to radiation exposure - Hematologic toxicity (e.g., thrombocytopen or leukocytopenia) - Persistent vomiting - Unusual skin rash or hives

Octreoscan should be administered ​​​​  ​  ​  ​  ​  ​   g  g ​  ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...  ... ...  ...  ... ... ... ... ... ... … … … … … … … … … … … … … ... … … … … … … …  … … … … … … … … … … … … 

-     t   t "  "   ewline  ewline \n   \